Contineum reports Q3 2026 results, PROPEL-IPF enrollment expands to over 100 sites
Contineum said its Phase 2 IPF trial of PIPE-791 now spans more than 100 sites in 16 countries, with cash runway projected through mid-2029.
Contineum Therapeutics reported third-quarter 2026 financial results on November 3, 2026. CEO Carmine Stengone said the company continues to expand its footprint for PROPEL-IPF, with over 100 sites now online in 16 countries to facilitate a steady pace of enrollment.1
PROPEL-IPF is a global Phase 2 trial testing PIPE-791 in idiopathic pulmonary fibrosis. The company initiated patient dosing in the trial in the first quarter of 2026.1 The randomized, double-blind, placebo-controlled study is evaluating the efficacy, safety, tolerability and pharmacokinetics of once-daily, oral PIPE-791 over 26 weeks of treatment in approximately 324 IPF patients.1 The primary efficacy endpoint is the change from baseline through week 26 in absolute forced vital capacity (FVC mL).1 The trial is listed on ClinicalTrials.gov under NCT07284459, according to the release.
On the pipeline, PIPE-791, an LPA1 receptor antagonist, is in clinical development for idiopathic pulmonary fibrosis and chronic pain, while PIPE-307 is a selective inhibitor of the M1 receptor in clinical development by Johnson & Johnson for major depressive disorder.1
On finances, cash, cash equivalents and marketable securities were $244.5 million as of September 30, 2026.1 Stengone said the projected cash runway extends through mid-2029, which the company said positions it with capital resources one year past the estimated completion of the IPF trial, and the company said its cash resources are sufficient to fund planned operations through mid-2029.1
Net loss was $18.7 million for the three months ended September 30, 2026, compared with $12.8 million in the third quarter of 2025.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.